tetano
Editor, Senior Moderator
Exp Gerontol. 2014 Jan 15. pii: S0531-5565(14)00009-6. doi: 10.1016/j.exger.2014.01.006. [Epub ahead of print]
Mucosal Adjuvants For Vaccines To Control Upper Respiratory Infections In The Elderly.
Fujihashi K1, Sato S2, Kiyono H3.
Author information
Abstract
Influenza virus and Streptococcus pneumoniae are two major pathogens that lead to significant morbidity and mortality in the elderly. Since both pathogens enter the host via the mucosa, especially the upper respiratory tract (URT), it is essential to elicit pathogen-specific secretory IgA (SIgA) antibody (Ab) responses at mucosal surfaces for defense of the elderly. However, as aging occurs, alterations in the mucosal immune system of older individuals result in a failure to induce SIgA Abs for protection from these infections. To overcome mucosal immunosenescence, we have developed a mucosal dendritic cell targeting, novel double adjuvant system which we show to be an attractive and effective immunological modulator. This system induces a more balanced Th1- and Th2- type cytokine response which supports both mucosal SIgA and systemic IgG1 and IgG2a Ab responses. Thus, adaptation of this adjuvant system to nasal vaccines for influenza virus and S. pneumoniae could successfully provide protection by supporting pathogen-specific SIgA Ab responses in the URT in the mouse model of aging. In summary, a double adjuvant system is considered to be an attractive and potentially important strategy for the future development of mucosal vaccines for the elderly.
Copyright ? 2014 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
SIgA, infectious disease, mucosa, respiratory tract, vaccine
PMID:
24440991
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24440991
Mucosal Adjuvants For Vaccines To Control Upper Respiratory Infections In The Elderly.
Fujihashi K1, Sato S2, Kiyono H3.
Author information
Abstract
Influenza virus and Streptococcus pneumoniae are two major pathogens that lead to significant morbidity and mortality in the elderly. Since both pathogens enter the host via the mucosa, especially the upper respiratory tract (URT), it is essential to elicit pathogen-specific secretory IgA (SIgA) antibody (Ab) responses at mucosal surfaces for defense of the elderly. However, as aging occurs, alterations in the mucosal immune system of older individuals result in a failure to induce SIgA Abs for protection from these infections. To overcome mucosal immunosenescence, we have developed a mucosal dendritic cell targeting, novel double adjuvant system which we show to be an attractive and effective immunological modulator. This system induces a more balanced Th1- and Th2- type cytokine response which supports both mucosal SIgA and systemic IgG1 and IgG2a Ab responses. Thus, adaptation of this adjuvant system to nasal vaccines for influenza virus and S. pneumoniae could successfully provide protection by supporting pathogen-specific SIgA Ab responses in the URT in the mouse model of aging. In summary, a double adjuvant system is considered to be an attractive and potentially important strategy for the future development of mucosal vaccines for the elderly.
Copyright ? 2014 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
SIgA, infectious disease, mucosa, respiratory tract, vaccine
PMID:
24440991
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24440991